Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Antidepressant Coverage | OpenP…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Antidepressants Step Therapy Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and step therapy approval for targeted antidepressant agents and specified duloxetine products under the Boeing commercial formulary. Coverage generally requires use, inadequate response, intolerance, contraindication, or another documented medical-necessity exception involving generic antidepressant or other prerequisite agents.

    Policy Summary
    PayerPrime Therapeutics
    PolicyAntidepressants Step Therapy Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit chart notes documenting the diagnosis, treatment history, prerequisite-agent trials and outcomes, and any applicable exception.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval duration
    180 daysRequested-agent lookback
    1Typical prerequisite
    BoeingFormulary

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Required
    Documentation

    Coverage Criteria

    Cymbalta Advanced Cancer Pathway

    Covered when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • The prescriber has stated that the patient has been diagnosed with stage four advanced, metastatic cancer and the requested agent is being used to treat the cancer.
      • The prescriber has submitted documentation that the patient has been diagnosed with stage four advanced, metastatic cancer and the requested agent is being used to treat an associated condition related to stage four advanced, metastatic cancer.

        Chart notes are required.

    • Use of the requested agent is consistent with best practices for treatment of stage four advanced, metastatic cancer or an associated condition, is supported by peer-reviewed, evidence-based literature, and is approved by the United States Food and Drug Administration.

    Cymbalta Initial or Exception Criteria

    Cymbalta is covered when ONE of the following initial-use or exception criteria is met:

    ONE of the following

    • The patient has been treated with the requested agent within the past 180 days.
    • ALL of the following

      • The patient is currently being treated with the requested agent.
      • The patient is currently stable on the requested agent.

        Chart notes are required.

    • The patient has tried and had an inadequate response to ONE generic prerequisite agent.

      Chart notes are required.

    Cymbalta and Drizalma Sprinkle Criteria

    The following pathways apply to Cymbalta and Drizalma Sprinkle when the requested agent is being considered for initial approval or an exception.

    ANY applicable pathway

    • The patient is currently receiving the requested agent and is stable on therapy.

      Chart notes are required.

    • The patient has tried and had an inadequate response to, has an intolerance or hypersensitivity to, or has an FDA-labeled contraindication to the applicable generic antidepressant prerequisites.

      Chart notes are required.

    • The patient has a diagnosis of neuropathic pain and has tried and had an inadequate response to, has an intolerance or hypersensitivity to, or has an FDA-labeled contraindication to ALL applicable prerequisite agents, including duloxetine delayed-release, amitriptyline, nortriptyline, desipramine, imipramine, or gabapentin.

      Chart notes are required.

    • The patient has a diagnosis of fibromyalgia and has tried and had an inadequate response to, has an intolerance or hypersensitivity to, or has an FDA-labeled contraindication to ALL applicable prerequisite agents, including duloxetine delayed-release, amitriptyline, nortriptyline, desipramine, imipramine, cyclobenzaprine, gabapentin, or tramadol.

    Cancer-Related Use

    Covered for cancer-related use when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • The prescriber has stated that the patient has been diagnosed with stage four advanced, metastatic cancer and the requested agent is being used to treat the cancer.
      • The prescriber has submitted documentation that the patient has been diagnosed with stage four advanced, metastatic cancer and the requested agent is being used to treat an associated condition related to stage four advanced, metastatic cancer.

        Chart notes are required.

    • Use of the requested agent is consistent with best practices for treatment of stage four advanced, metastatic cancer or an associated condition, is supported by peer-reviewed, evidence-based literature, and is approved by the United States Food and Drug Administration.

    Initial Target-Agent Approval Criteria

    Initial approval of the requested target agent is provided when ANY one qualifying pathway is met. Chart notes are required wherever specified.

    ANY qualifying pathway

    • The patient has been treated with the requested agent within the past 180 days.
    • ALL of the following

      • The patient is currently being treated with the requested agent.
      • The patient is currently stable on the requested agent.

        Chart notes are required.

    • The patient has tried and had an inadequate response to a generic antidepressant agent, such as an SSRI, SNRI, bupropion, mirtazapine, or vilazodone.

      Chart notes are required.

    Authorization and Documentation Requirements

    Prior Authorization

    Clinical Criteria Required

    Prior authorization is required for the applicable antidepressant target agents. Approval requires meeting at least one clinical pathway and submitting the supporting information identified in the criteria.

    • Approval is generally limited to a 12-month period.
    • If a quantity limit applies, refer to the applicable Quantity Limit Criteria.
    Step Therapy

    Use a Generic Prerequisite

    For most brand target agents other than Cymbalta and Drizalma Sprinkle, document use of at least one qualifying generic prerequisite before requesting the brand agent.

    • The prerequisite may be any one generic antidepressant agent, including an SSRI, SNRI, bupropion, mirtazapine, or vilazodone.
    • For Auvelity, the prerequisite may be a generic antidepressant or a generic atypical antipsychotic.

    Policy Scope and Context

    This policy applies step therapy to antidepressant products, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), bupropion, mirtazapine, vilazodone, and newer branded agents. Most targeted brand agents require use of one generic antidepressant prerequisite before approval. Separate pathways address Cymbalta (duloxetine delayed-release) and Drizalma Sprinkle, including selected uses for depression-related treatment, neuropathic pain, fibromyalgia, chronic musculoskeletal pain, and conditions associated with stage four advanced or metastatic cancer. Exceptions may apply when prerequisite therapy is ineffective, not tolerated, contraindicated, unsafe, medically inappropriate, or likely to impair adherence or functional ability.

    Policy Definitions

    Generic antidepressant agent
    Selective serotonin reuptake inhibitors (SSRIs)Included as a generic antidepressant agent.
    Serotonin-norepinephrine reuptake inhibitors (SNRIs)Included as a generic antidepressant agent.
    BupropionIncluded as a generic antidepressant agent.
    MirtazapineIncluded as a generic antidepressant agent.
    VilazodoneIncluded as a generic antidepressant agent.
    Product availability notation
    Asterisk (*)Identifies a brand product with a generic available.

    Initial Therapy Criteria

    Cymbalta Initial Approval

    Cymbalta is approved when ONE of the following pathways is met:

    Initial Cymbalta pathways

    • Advanced metastatic cancer: The patient meets the stage four advanced or metastatic cancer pathway, including the required cancer-related use, evidence, best-practice, and FDA-support criteria.
    • Generic prerequisite or exception

      • The patient has tried and had an inadequate response to one generic prerequisite agent.

        Chart notes are required.

      • One generic prerequisite agent was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event.

        Chart notes are required.

    Continuation and Established Therapy

    Recent or Stable Treatment

    Continuation or established therapy is approved when ANY of the following applies:

    Established therapy

    • The patient has been treated with the requested agent within the past 180 days.180 days
    • The patient is currently being treated with and stable on the requested agent.

      Chart notes are required.

    Continuation of Requested Agent

    Continuation is supported when ANY of the following applies:

    Continuation treatment

    Prerequisite Therapy Pathways

    StepTarget agentsRequirement
    1Most targeted brand antidepressants other than Cymbalta and Drizalma SprinkleUse any one generic antidepressant agent, such as an SSRI, SNRI, bupropion, mirtazapine, or vilazodone, before approval.
    StepTarget agentRequirement
    1CymbaltaTry one generic prerequisite agent, or document a qualifying exception such as inadequate response, discontinuation for lack of efficacy, diminished effect, or an adverse event; intolerance or hypersensitivity; contraindication to all generic prerequisites; expected ineffectiveness or harm; a significant adherence or functional barrier; or medical necessity.
    StepTarget agents and usePrerequisite or exception
    1Cymbalta or Drizalma Sprinkle for neuropathic painUse, or document inadequate response, intolerance or hypersensitivity, or an FDA-labeled contraindication involving an applicable prerequisite: duloxetine delayed-release, amitriptyline, nortriptyline, desipramine, imipramine, or gabapentin.
    StepApplicable useRequirement
    1Depression-related or diagnosis-specific useTry an applicable generic antidepressant or diagnosis-specific prerequisite agent, unless an exception is documented. Exceptions include inadequate response, intolerance or hypersensitivity, an FDA-labeled contraindication, qualifying discontinuation, or documented medical necessity.
    StepAlternative prerequisiteDocumentation required
    2Another prescription drug in the same pharmacologic class or with the same mechanism of action as the prerequisite agentThe alternative drug may satisfy the prerequisite requirement when it was discontinued because of lack of efficacy or effectiveness, diminished effect, or an adverse event; chart notes are required.
    Policy Summary
    PayerPrime Therapeutics
    PolicyAntidepressants Step Therapy Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit chart notes documenting the diagnosis, treatment history, prerequisite-agent trials and outcomes, and any applicable exception.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsPolicy Scope and ContextPolicy DefinitionsInitial Therapy CriteriaContinuation and Established TherapyPrerequisite Therapy Pathways
    ONE generic prerequisite agent was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event.

    Chart notes are required.

  1. The patient has an intolerance or hypersensitivity to ONE generic prerequisite agent.

    Chart notes are required.

  2. The patient has an FDA-labeled contraindication to ALL generic prerequisites.

    Chart notes are required.

  3. ONE generic prerequisite agent is expected to be ineffective based on the known clinical characteristics of the patient and the known characteristics of the prescription drug; cause a significant barrier to adherence of care; worsen a comorbid condition; decrease the patient's ability to achieve or maintain reasonable functional ability in performing daily activities; or cause an adverse reaction or physical or mental harm.

    Chart notes are required.

  4. ONE generic prerequisite agent is not in the best interest of the patient based on medical necessity.

    Chart notes are required.

  5. The patient has tried another prescription drug in the same pharmacologic class or with the same mechanism of action as ONE generic prerequisite agent, and that prescription drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event.

    Chart notes are required.

  6. Chart notes are required.

  7. The patient has a diagnosis of chronic musculoskeletal pain and has tried and had an inadequate response to, has an intolerance or hypersensitivity to, or has an FDA-labeled contraindication to ALL applicable prerequisite agents, including duloxetine delayed-release, acetaminophen, oral NSAID, topical NSAID, tramadol, amitriptyline, nortriptyline, desipramine, imipramine, cyclobenzaprine, or gabapentin.

    Chart notes are required.

  8. A prerequisite agent was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event.

    Chart notes are required.

  9. The requested agent is being used for a diagnosis other than neuropathic pain, fibromyalgia, or chronic musculoskeletal pain, and the patient has an intolerance or hypersensitivity to a generic antidepressant or an FDA-labeled contraindication to ALL generic antidepressants.

    Chart notes are required.

  10. The patient has an intolerance or hypersensitivity to a generic antidepressant agent, such as an SSRI, SNRI, bupropion, mirtazapine, or vilazodone.

    Chart notes are required.

  11. The patient has an FDA-labeled contraindication to ALL generic antidepressants, such as an SSRI, SNRI, bupropion, mirtazapine, or vilazodone.

    Chart notes are required.

  12. The patient has a diagnosis of neuropathic pain and has tried and had an inadequate response to, has an intolerance or hypersensitivity to, or has an FDA-labeled contraindication to the applicable prerequisite agents: duloxetine delayed-release, amitriptyline, nortriptyline, desipramine, imipramine, or gabapentin.

    Chart notes are required.

  13. The patient has a diagnosis of fibromyalgia and has tried and had an inadequate response to, has an intolerance or hypersensitivity to, or has an FDA-labeled contraindication to the applicable prerequisite agents: duloxetine delayed-release, amitriptyline, nortriptyline, desipramine, imipramine, cyclobenzaprine, gabapentin, or tramadol.

    Chart notes are required.

  14. The patient has a diagnosis of chronic musculoskeletal pain and has tried and had an inadequate response to, has an intolerance or hypersensitivity to, or has an FDA-labeled contraindication to the applicable prerequisite agents: duloxetine delayed-release, acetaminophen, oral NSAID, topical NSAID, tramadol, amitriptyline, nortriptyline, desipramine, imipramine, cyclobenzaprine, or gabapentin.

    Chart notes are required.

  15. A prerequisite agent was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event.

    Chart notes are required.

  16. A prerequisite agent is expected to be ineffective based on the known clinical characteristics of the patient and the known characteristics of the prescription drug; cause a significant barrier to adherence of care; worsen a comorbid condition; decrease the patient's ability to achieve or maintain reasonable functional ability in performing daily activities; or cause an adverse reaction or physical or mental harm.

    Chart notes are required.

  17. A prerequisite agent is not in the best interest of the patient based on medical necessity.

    Chart notes are required.

  18. The patient has tried another prescription drug in the same pharmacologic class or with the same mechanism of action as a prerequisite agent, and that prescription drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event.

    Chart notes are required.

  19. If used for a diagnosis other than neuropathic pain, fibromyalgia, or chronic musculoskeletal pain, the patient has an intolerance or hypersensitivity to a generic antidepressant or an FDA-labeled contraindication to ALL generic antidepressants.

    Chart notes are required.

  20. Prior Authorization

    Target-Agent Authorization

    For Cymbalta (duloxetine delayed-release) and Drizalma Sprinkle (duloxetine delayed-release sprinkle capsule), obtain authorization by documenting one of the cancer, continuation, generic-antidepressant, diagnosis-specific prerequisite, or qualifying exception pathways.

    • Both agents have generic availability noted in the criteria.
    • The requested agent is generally approved for 12 months when a pathway is met.
    Step Therapy

    Generic Antidepressant Step

    For applicable brand antidepressant requests, document a trial of any one generic antidepressant agent before requesting the brand product.

    • Qualifying classes are SSRI, SNRI, bupropion, mirtazapine, or vilazodone.
    • The criteria may alternatively allow intolerance, hypersensitivity, or an FDA-labeled contraindication to all generic antidepressants when documented.
    Step Therapy

    Cymbalta Prerequisite Exception

    Cymbalta may qualify without the standard generic prerequisite when a qualifying exception is documented. Exceptions include recent or current stable use, inadequate response, discontinuation, intolerance or hypersensitivity, contraindication, expected ineffectiveness or harm, medical-necessity concerns, or failure of a same-class or same-mechanism drug.

    • Recent treatment means treatment with the requested agent within the past 180 days.
    • A generic prerequisite may be excepted when it is expected to be ineffective, impair adherence or function, worsen a comorbid condition, cause harm, or otherwise not be in the patient's best interest.
    • Document the applicable exception in chart notes.
    Step Therapy

    Duloxetine Generic Antidepressant Step

    For duloxetine used for depression or another indication requiring the antidepressant pathway, document an inadequate response, intolerance or hypersensitivity, or FDA-labeled contraindication involving the required generic antidepressant step.

    • The generic antidepressant step includes an SSRI, SNRI, bupropion, mirtazapine, or vilazodone.
    • For uses other than neuropathic pain, fibromyalgia, or chronic musculoskeletal pain, intolerance or contraindication to generic antidepressants may support approval.
    Step Therapy

    Neuropathic Pain Prerequisite Step

    For neuropathic pain, document the diagnosis and one qualifying prerequisite pathway before requesting duloxetine delayed-release.

    • The prerequisite list includes duloxetine delayed-release, amitriptyline, nortriptyline, desipramine, imipramine, or gabapentin.
    • A qualifying pathway is inadequate response, intolerance or hypersensitivity to one prerequisite, or an FDA-labeled contraindication to all prerequisites.
    Step Therapy

    Prerequisite Therapy or Exception

    For fibromyalgia or chronic musculoskeletal pain, document a trial of, or a qualifying exception involving, an applicable prerequisite agent. A prerequisite may be satisfied by inadequate response, intolerance or hypersensitivity, an FDA-labeled contraindication to all listed agents, or discontinuation for lack of efficacy, diminished effect, or an adverse event.

    • Fibromyalgia prerequisites include duloxetine delayed-release, amitriptyline, nortriptyline, desipramine, imipramine, cyclobenzaprine, gabapentin, or tramadol.
    • Chronic musculoskeletal pain prerequisites include duloxetine delayed-release, acetaminophen, oral or topical NSAIDs, tramadol, amitriptyline, nortriptyline, desipramine, imipramine, cyclobenzaprine, or gabapentin.
    • A same-class or same-mechanism prescription drug discontinued for lack of efficacy, diminished effect, or an adverse event may also support the exception.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Documentation Required

    Required Chart Documentation

    Submit complete clinical records supporting the requested pathway, including diagnosis, requested-agent use, prerequisite trials, treatment outcomes, and any applicable exception.

    • Include chart notes for inadequate response, intolerance, hypersensitivity, contraindication, discontinuation, adverse events, or current stability.
    • For diagnosis-specific requests, identify whether the use is for neuropathic pain, fibromyalgia, chronic musculoskeletal pain, or another condition.
    • Document the relevant prerequisite agents and the reason each required criterion is met.
    Documentation Required

    Cancer-Related Documentation

    For cancer-related requests, provide the cancer diagnosis and show that Cymbalta or Drizalma Sprinkle is being used to treat the cancer or an associated condition related to stage four advanced, metastatic cancer.

    • Chart notes are required when the prescriber submits documentation of the diagnosis and associated use.
    • Support that the requested use is consistent with best practices, peer-reviewed evidence, and FDA approval.
    Denial Risk

    No Qualifying Prerequisite or Exception

    A request may be denied when the required generic prerequisite has not been tried and no qualifying exception is documented.

    • Do not rely on an undocumented clinical rationale or an unlisted prerequisite.
    • For the applicable pathway, document either the required trial or a qualifying exception.
    Denial Risk

    Required Chart Notes Missing

    Missing chart notes can prevent approval even when the patient may otherwise meet a prerequisite exception or diagnosis-specific pathway.

    • Records must support current stability, inadequate response, discontinuation, intolerance, hypersensitivity, contraindication, or other stated exception.
    • Include the diagnosis and requested-agent use when relying on cancer, neuropathic pain, fibromyalgia, or musculoskeletal pain criteria.
    Denial Risk

    Failure to Meet an Approval Pathway

    The request may be denied when the patient does not meet at least one applicable approval pathway for the requested agent.

    • Failure to meet the continuation, generic-antidepressant, diagnosis-specific prerequisite, cancer, or exception criteria may result in denial.
    • For uses outside neuropathic pain, fibromyalgia, or chronic musculoskeletal pain, the applicable generic-antidepressant exception criteria must still be met.
    Denial Risk

    Insufficient Clinical Documentation

    Incomplete treatment-history documentation may result in denial because the criteria require evidence of prerequisite therapy or a documented exception.

    • Identify the agent tried, the clinical response, dates or duration when available, and the reason for discontinuation.
    • Document all required chart-note elements for inadequate response, intolerance, hypersensitivity, contraindication, adverse event, or medical necessity.
    • A diagnosis alone does not replace the required prerequisite or exception documentation.
    Caret (^)Identifies a branded generic product available.
    Product-list notationThe asterisk and caret are used to show product availability status in the policy's target-agent listings.
  21. The patient has an intolerance or hypersensitivity to one generic prerequisite agent.

    Chart notes are required.

  22. The patient has an FDA-labeled contraindication to all generic prerequisites.

    Chart notes are required.

  23. A generic prerequisite is expected to be ineffective or harmful, create a significant adherence or functional barrier, worsen a comorbid condition, or otherwise not be in the patient's best interest based on medical necessity.

    Chart notes are required.

  24. The patient tried another prescription drug in the same pharmacologic class or with the same mechanism of action as one generic prerequisite, and that drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event.

    Chart notes are required.

  25. Cymbalta or Drizalma Sprinkle Initial Approval

    Cymbalta and Drizalma Sprinkle are approved when the applicable clinical criteria are met:

    Initial duloxetine product pathways

    • Depression-related use: The patient has an inadequate response to, intolerance or hypersensitivity to, or an FDA-labeled contraindication involving the applicable generic antidepressant prerequisite pathway.

      Chart notes are required.

    • Neuropathic pain: The patient has a diagnosis of neuropathic pain and meets the applicable prerequisite-agent trial, intolerance, hypersensitivity, or contraindication pathway.

      Prerequisites include duloxetine delayed-release, amitriptyline, nortriptyline, desipramine, imipramine, and gabapentin; chart notes are required.

    • Fibromyalgia: The patient has fibromyalgia and meets the additional prerequisite-agent criteria stated in the policy.

      The complete fibromyalgia criteria continue beyond the available source window.

    Initial Target-Agent Approval

    Initial approval requires ANY one of the following pathways:

    Initial target-agent approval pathways

    • The patient has been treated with the requested agent within the past 180 days or is currently being treated with and stable on it.180 days

      Chart notes are required for current stability.

    • The patient has an inadequate response to, intolerance or hypersensitivity to, or an FDA-labeled contraindication involving generic antidepressants.

      Chart notes are required.

    • The patient has a diagnosis-specific prerequisite pathway for neuropathic pain, fibromyalgia, or chronic musculoskeletal pain.

      Chart notes are required.

    • A prerequisite agent was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event.

      Chart notes are required.

    • A prerequisite agent is not in the patient's best interest based on medical necessity, or would create a significant adherence barrier, worsen a comorbid condition, reduce functional ability, or cause an adverse reaction or physical or mental harm.

      Chart notes are required.

    • The patient tried another prescription drug in the same pharmacologic class or with the same mechanism of action as a prerequisite agent, and that drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event.

      Chart notes are required.

    • For a diagnosis other than neuropathic pain, fibromyalgia, or chronic musculoskeletal pain, the patient has an intolerance or hypersensitivity to a generic antidepressant or an FDA-labeled contraindication to all generic antidepressants.
    The patient has been treated with the requested agent within the past 180 days.180 days
  26. The prescriber states that the patient is currently being treated with and stable on the requested agent.

    Chart notes are required.